ReNeuron's stem cell products are derived from non-embryonic human tissue sources. Our stem cell therapy programmes have been built around our unique and highly efficient stem cell expansion technology. This platform enables, from a single tissue sample, the growth of selected human stem cells into banks of quality-assured stem cell lines. These stem cell lines contain enough stem cells to treat many hundreds of thousands of potential patients. This capability has enabled us to focus on developing off-the-shelf, or allogeneic, stem cell treatments addressing diseases with large patient populations. The stem cell expansion process is fully regulated by way of a chemically induced safety switch so that cell growth can be arrested before implantation of the stem cells into the patient.

Using our cell expansion technology, we are able to readily scale-up our stem cell lines for clinical and commercial use without the need to re-derive those cell lines from an earlier, non-quality assured prototype. This gives ReNeuron a significant competitive advantage in terms of the time and expense in moving a potential stem cell therapy through a clinical development programme.

We have also developed a unique screening platform that enables the selection of optimal stem cell lines for further development as a treatment for the relevant disease. Selection criteria during cell screening include cell phenotype, ability to expand into large-scale culture, and capacity to engraft in the relevant disease model with minimal immune rejection by the host.

The results of pre-clinical testing of our various technologies and stem cell products have been published in nine peer-reviewed scientific journals to date.